SAB Capital Expenditures vs Begin Period Cash Flow Analysis
SABS Stock | USD 3.96 0.12 2.94% |
SAB Biotherapeutics financial indicator trend analysis is much more than just breaking down SAB Biotherapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether SAB Biotherapeutics is a good investment. Please check the relationship between SAB Biotherapeutics Capital Expenditures and its Begin Period Cash Flow accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SAB Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.
Capital Expenditures vs Begin Period Cash Flow
Capital Expenditures vs Begin Period Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of SAB Biotherapeutics Capital Expenditures account and Begin Period Cash Flow. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between SAB Biotherapeutics' Capital Expenditures and Begin Period Cash Flow is -0.59. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of SAB Biotherapeutics, assuming nothing else is changed. The correlation between historical values of SAB Biotherapeutics' Capital Expenditures and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of SAB Biotherapeutics are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Capital Expenditures i.e., SAB Biotherapeutics' Capital Expenditures and Begin Period Cash Flow go up and down completely randomly.
Correlation Coefficient | -0.59 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Capital Expenditures
Capital Expenditures are funds used by SAB Biotherapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of SAB Biotherapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most indicators from SAB Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into SAB Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SAB Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.At this time, SAB Biotherapeutics' Sales General And Administrative To Revenue is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.35 in 2024, whereas Tax Provision is likely to drop 0.00 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 1.7M | 3.3M | 3.7M | 2.1M | Interest Income | 23.1K | 71.1K | 130.8K | 80.1K |
SAB Biotherapeutics fundamental ratios Correlations
Click cells to compare fundamentals
SAB Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.